Johnson & Johnson : Services, Inc. - Statement attributed to Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson
July 10, 2020 at 06:17 am
Share
Antimicrobial resistance (AMR) develops when infectious disease pathogens become resistant to existing medicines and is a significant public health threat.
AMR has the potential to render diseases that are relatively easy to treat today virtually incurable, a problem that threatens developed and developing nations alike. Left unchecked, AMR could significantly eclipse the global health challenge that the world is facing currently with COVID-19. That's why the pharmaceutical industry is taking collective and decisive action in the face of this predictable and preventable health security threat.
Johnson & Johnson is proud to join with more than 20 leading pharmaceutical companies to collectively invest nearly $1 billion through the AMR Action Fund with the goal of bringing 2-to-4 new antibiotics to patients by the end of the next decade. This is the largest collective venture ever created to address AMR, acknowledging that this is a challenge that requires immediate action. As a founding partner, we are committing $100 million to the Fund. Together, our industry can make a far greater impact than any single company, and we are proud to stand with our peers against this threat.
Our participation in the Fund builds on our long-term commitment to develop and responsibly deploy innovative technologies and treatments to combat the growing threat of AMR on multiple fronts. This commitment is exemplified in our work to tackle drug-resistant tuberculosis (DR-TB). DR-TB is responsible for one-third of all AMR-related deaths and is the world's only airborne drug-resistant infection. Currently, a third of all people with DR-TB are not aware they are infected, posing a dangerous threat to public health and global health security.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Johnson & Johnson : Services, Inc. - Statement attributed to Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson